NCT06045156 Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke
| NCT ID | NCT06045156 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The First Hospital of Jilin University |
| Condition | Acute Ischemic Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,084 participants |
| Start Date | 2024-04-29 |
| Primary Completion | 2026-01-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,084 participants in total. It began in 2024-04-29 with a primary completion date of 2026-01-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of early tirofiban administration in patients undergoing IVT
Eligibility Criteria
Inclusion Criteria: 1. Age≥18 years old; 2. Clinically diagnosed as acute ischemic stroke and received standard dose (0.25mg/kg) of tenecteplase IVT within 4.5 hours of onset; 3. Total National Institute of Health stroke scale (NIHSS)≥4 or single limb motor item score≥2, and total NIHSS≤15 after IVT; 4. Tirofiban or placebo treatment can be initiated within 6h after IVT; 5. mRS score before onset≤ 1; 6. Intracranial hemorrhage is ruled out by CT head after IVT; Exclusion Criteria: 1. Received or plan to undergo bridge therapy; 2. Large area of infarct indicated by radiological imaging(≥1/3 of middle cerebral artery supply area); 3. Atrial fibrillation or suspected cardiac embolism; 4. Accompanied by epileptic seizures; 5. Using antiplatelet, anticoagulant or fibrinolytic agents within 24h before recruitment; 6. Active bleeding or tendency to bleed after receipt of intravenous thrombolysis; 7. Digestive system bleeding, urinary system bleeding, hemorrhagic retinopathy or other systemic bleeding events within 1 year; 8. Severe renal or liver insufficiency; ALT or AST\>3 times of the upper limit of normal value or above; creatinine clearance rate\<30 mL/min, creatinine\>200μmol/L； 9. Life expectancy less than 3 months; 10. Pregnant or lactating women; 11. Known allergy to tirofiban; 12. Being enrolled or having been enrolled in other clinical trial within 3 months prior to this clinical trial.; 13. Patients who are unwilling to be followed up or likely to have poor treatment compliance; 14. Other situations that the researcher deems unsuitable for inclusion in the study.
Frequently Asked Questions
Who can join the NCT06045156 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06045156 currently recruiting?
Yes, NCT06045156 is actively recruiting participants. Visit ClinicalTrials.gov or contact The First Hospital of Jilin University to inquire about joining.
Where is the NCT06045156 trial being conducted?
This trial is being conducted at Changchun, China.
Who is sponsoring the NCT06045156 clinical trial?
NCT06045156 is sponsored by The First Hospital of Jilin University. The trial plans to enroll 1,084 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.